share_log

金城医药(300233.SZ)：注射用头孢哌酮钠舒巴坦钠收到药品补充申请批准通知书

Shandong Jincheng Pharmaceutical Group (300233.SZ): the drug supplement application approval notice for injection of Cefoperazone sodium and Sulbactam sodium has been received.

Gelonghui Finance ·  Jul 10 07:36

On July 10th, Gelunhui reported that Shandong Jincheng Pharmaceutical Group (300233.SZ), a holding subsidiary, has recently received the "Drug Supplement Application Approval Notice" for injection of cefoperazone sodium with sulbactam sodium issued by the National Medical Products Administration. Cefoperazone sodium with sulbactam sodium for injection is a combination of the third-generation cephalosporins and β-lactamase inhibitors. It can be used alone to treat upper and lower respiratory tract infections caused by sensitive bacteria, urinary tract infections, peritonitis, cholecystitis, cholangitis, and other intra-abdominal infections, sepsis, meningitis, skin and soft tissue infections, bone and joint infections, pelvic inflammatory disease, endometritis, gonorrhea, and other reproductive tract infections, and can be used in combination with other antibiotics.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment